摘要
阿尔茨海默病(AD)的神经心理学相关冷漠可帮助发现神经生物学的这种行为异常。鉴于先前研究显示AD冷漠与执行功能有关联,遗忘型轻度认知损伤(aMCI) 队列表明与记忆测试有关。采用简单执行测试,也就是执行访问(EXIT-25)和额叶功能评定量表(FAB),我们旨在用低教育、从未接触到胆碱酯酶抑制剂、aMCI (n=26)和轻度AD (n=28)病人的样本进一步研究这个问题。Pietà研究,病人和对照组(n=33)包括来自对巴西老年人(75+ years)脑衰老的成功的社区调查。递交了参与者综合的神经心理学评估和通过情感冷漠量表(AS)的冷漠评估。通过痴呆残疾评估检测,我们发现AD组的AS得分与功能特性有很强的相关性(rho =-0.7 ; p<0,001)。任何执行测试性能与冷漠症状没有关联。冷漠症状也与Mattis痴呆评定量表的记忆力测验和注意力评分性能相关。这些发现加强了甚至在最轻度阶段的AD认知损害范围中的冷漠功能效应,及前期假设的关于冷漠与传统执行功能之间关联的挑战。
关键词: 阿尔茨海默病,冷漠,执行能力,功能性,记忆,轻度认知功能障碍
Current Alzheimer Research
Title:Apathy Is not Associated with Performance in Brief Executive Tests in Patients with Mild Cognitive Impairment and Mild Alzheimers Disease
Volume: 11 Issue: 8
Author(s): Henrique Cerqueira Guimaraes, Patricia Paes Fialho, Viviane Amaral Carvalho, Thais Helena Machado, Etelvina Lucas Santos and Paulo Caramelli
Affiliation:
关键词: 阿尔茨海默病,冷漠,执行能力,功能性,记忆,轻度认知功能障碍
摘要: Neuropsychological correlates of apathy in Alzheimer’s disease (AD) may shed some light on the neurobiology of this behavioral disorder. Whereas previous research has suggested an association between apathy and executive functions in AD, amnestic mild cognitive impairment (aMCI) cohorts point to an association with memory tests. We aimed to further investigate this issue in a sample of low educated, hitherto unexposed to cholinesterase inhibitors, aMCI (n=26) and mild AD (n=28) patients using brief executive tests, namely the Executive Interview (EXIT-25) and the Frontal Assessment Battery (FAB). Patients and controls (n=33) were included from a community-based survey of successful brain aging in Brazilian elderly (75+ years), The Pietà Study. The participants were submitted to a comprehensively neuropsychological assessment and apathy evaluation through the Apathy Scale (AS).We found a strong correlation in AD group between AS scores and functional performance measured by the Disability Assessment in Dementia (rho =-0.7 ; p<0,001). No association was found between any executive test performance and apathy symptoms. Apathy symptoms were also associated with the performance in memory tests and in the attention subscale of the Mattis Dementia Rating Scale. These findings reinforce the functional effect of apathy even in the mildest stages along the AD cognitive impairment spectrum, and challenges previous assumptions regarding the association between apathy and classical executive functions.
Export Options
About this article
Cite this article as:
Henrique Cerqueira Guimaraes, Patricia Paes Fialho, Viviane Amaral Carvalho , Thais Helena Machado, Etelvina Lucas Santos and Caramelli Paulo, Apathy Is not Associated with Performance in Brief Executive Tests in Patients with Mild Cognitive Impairment and Mild Alzheimers Disease, Current Alzheimer Research 2014; 11 (8) . https://dx.doi.org/10.2174/156720501108140910122509
DOI https://dx.doi.org/10.2174/156720501108140910122509 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alcohol Abuse and HIV Infection: Role of DRD2
Current HIV Research Alzheimers Disease and Oxidative Stress: The Old Problem Remains Unsolved
Current Medicinal Chemistry - Central Nervous System Agents Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders
Current Pharmaceutical Design Protein Folding and Misfolding, Endoplasmic Reticulum Stress in Neurodegenerative Diseases: in Trace of Novel Drug Targets
Current Protein & Peptide Science Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology Thrombolysis in Ischemic Stroke: Focus on New Treatment Strategies
Recent Patents on Cardiovascular Drug Discovery Asymmetric Dimethylarginine: A Possible Link between Vascular Disease and Dementia
Current Alzheimer Research Antiplatelet Therapies: Aspirin at the Heart of New Directions
Cardiovascular & Hematological Disorders-Drug Targets Commentary (Complement-Initiated Neuroinflammation and Its Role in Early Stage Alzheimers Disease)
Current Alzheimer Research Immune-Inflammatory Activation in Acute Coronary Syndromes: A Look into the Heart of Unstable Coronary Plaque
Current Cardiology Reviews Covid-19 in Man: A Very Dangerous Affair
Endocrine, Metabolic & Immune Disorders - Drug Targets Heterocyclic Amaryllidaceae Alkaloids: Biosynthesis and Pharmacological Applications
Current Topics in Medicinal Chemistry Molecular Genetics of Early- and Late-Onset Alzheimer’s Disease
Current Gene Therapy Psychopathological Behaviour and Cognition in Morbid Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) HIV and Substance Abuse: A Commentary
Current HIV Research Commentary (Research Highlights: Targeted Inhibition of miR-155 Promotes Post-Stroke Neovascularization and Functional Recovery)
CNS & Neurological Disorders - Drug Targets Linking New Paradigms in Protein Chemistry to Reversible Membrane-Protein Interactions
Current Protein & Peptide Science Editorial [Hot topic: Tau, Neurodegeneration and Alzheimers Disease (Guest Editor: Alejandra del Carmen Alonso)]
Current Alzheimer Research γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes
Current Topics in Medicinal Chemistry Cholesterol Homeostasis Failure in the Brain: Implications for Synaptic Dysfunction and Cognitive Decline
Current Medicinal Chemistry